Examples of 'vandetanib' in a sentence
Meaning of "vandetanib"
vandetanib (noun) - a drug commonly used in the treatment of thyroid cancer
Show more definitions
- An anticancer drug used to treat certain tumors of the thyroid gland.
How to use "vandetanib" in a sentence
Basic
Advanced
vandetanib
Vandetanib has shown no mutagenic or clastogenic potential.
Caprelsa contains the active substance vandetanib.
Vandetanib had no effect on fertility in male rats.
These elements gradually disappear when vandetanib is discontinued.
Vandetanib treatment must not be started in patients.
Objective response rate vandetanib arm.
Effect of vandetanib on other medicinal products.
It may not be reversible on stopping vandetanib.
Exposure to vandetanib is not affected by food.
Caprelsa is a medicine that contains the active substance vandetanib.
Take vandetanib exactly as directed.
The active substance is vandetanib.
Vandetanib also showed evidence of phototoxic potential in an in vitro cytotoxicity assay.
Heart failure has been observed in patients who received vandetanib.
Vandetanib has shown no carcinogenic potential in a transgenic mouse carcinogenicity study.
See also
There is a limited amount of data on the use of vandetanib during pregnancy.
Vandetanib and cabozantinib are used to treat some medullary thyroid cancers.
Diarrhoea is a disease related symptom as well as a known undesirable effect of vandetanib.
Vandetanib is not recommended in paediatric patients with severe renal impairment.
Alanine aminotransferase elevations occur commonly in patients treated with vandetanib.
This suggests that vandetanib slows but does not prevent wound healing.
Effects on reproduction in paediatric patients treated with vandetanib are not known.
Biliary excretion of unchanged vandetanib is one of the excretion pathways for vandetanib.
Vandetanib has not been studied in patients with ventricular arrhythmias or recent myocardial infarction.
Food effect Exposure to vandetanib is not affected by food.
Vandetanib also inhibited the growth of MTC xenograft tumours in vivo.
PRES has also been observed in patients receiving vandetanib as monotherapy.
Patients were treated with vandetanib or placebo until they reached objective disease progression.
Ocular events such as blurred vision are common in patients who received vandetanib for MTC.
AstraZeneca will work to make vandetanib available to patients as soon as possible.
Vandetanib may be administered until patients with MTC are no longer benefiting from treatment.
The precise mechanism of action of vandetanib in locally advanced or metastatic MTC is unknown.
Vandetanib prolongs the QTc interval and can cause Torsades de pointes and sudden death.
Conditions treated by Vandetanib.
Vandetanib is also under regulatory review in the European Union and Canada.
Breast-feeding is contraindicated while receiving vandetanib therapy.
Therefore, vandetanib is not indicated for use in paediatric patients.
There are no data on the use of vandetanib in breast-feeding women.
In mice, vandetanib was shown to delay but not prevent wound healing.
Therefore, the concomitant use of ondansetron with vandetanib is not recommended.
Vandetanib inhibits EGFR-dependent cell proliferation and cell survival in vitro.
Therefore, the concomitant use of ondansetron with vandetanib is not-recommended.
Vandetanib has shown no carcinogenic potential effect in a 6 month carcinogenicity study in rasH2 transgenic mice.
Hypertension, including hypertensive crisis, has been observed in patients treated with vandetanib.
Details of medicinal products where the co-administration of vandetanib is either contraindicated or not recommended.
If ILD is confirmed, vandetanib should be permanently discontinued and the patient treated appropriately.
Patients who develop a single value of a QTc interval of ≥ 500 msec should stop taking vandetanib.
The concomitant use of vandetanib with ondansetron is not recommended see section 4.5.
The study will include approximately 60 % of patients who receive vandetanib within the EU.
Vandetanib is also a sub-micromolar inhibitor of vascular endothelial receptor-3 tyrosine kinase.
